Arbaclofen: Phase II data

In the per protocol (PP) population (n=25) of an open-label, U.S. Phase II trial, STX209 met the primary endpoint of significantly improving irritability subscale scores on the ABC-I from baseline to week 8 (p<0.001). STX209 also

Read the full 368 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE